Anixa Biosciences, Inc. (ANIX)
USD 2.64
(-0.75%)
USD 2.64
(-0.75%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 49 Thousand USD | -100.0% |
| 2022 | 2.46 Billion USD | 1936368.02% |
| 2021 | 127.49 Thousand USD | 241.42% |
| 2020 | -90.15 Thousand USD | -207.65% |
| 2019 | 83.75 Thousand USD | -75.66% |
| 2018 | 344.09 Thousand USD | 33.4% |
| 2017 | 257.94 Thousand USD | 212.34% |
| 2016 | 82.58 Thousand USD | -98.53% |
| 2015 | 5.6 Million USD | 233.87% |
| 2014 | 1.67 Million USD | 2226.08% |
| 2013 | 72.19 Thousand USD | -92.29% |
| 2012 | 936.13 Thousand USD | -3.4% |
| 2011 | 969.11 Thousand USD | 49.47% |
| 2010 | 648.36 Thousand USD | -34.52% |
| 2009 | 990.1 Thousand USD | -49.68% |
| 2008 | 1.96 Million USD | 502.63% |
| 2007 | 326.49 Thousand USD | -7.3% |
| 2006 | 352.2 Thousand USD | 225.86% |
| 2005 | -279.84 Thousand USD | -187.9% |
| 2004 | 318.35 Thousand USD | 366.26% |
| 2003 | 68.27 Thousand USD | -97.94% |
| 2002 | 3.31 Million USD | 233.86% |
| 2001 | 993.12 Thousand USD | -1.51% |
| 2000 | 1 Million USD | 152.09% |
| 1999 | 400 Thousand USD | 0.0% |
| 1998 | 400 Thousand USD | 0.0% |
| 1997 | 400 Thousand USD | 100.0% |
| 1996 | 200 Thousand USD | 0.0% |
| 1995 | 200 Thousand USD | 0.0% |
| 1994 | 200 Thousand USD | 100.0% |
| 1993 | 100 Thousand USD | 0.0% |
| 1992 | 100 Thousand USD | 0.0% |
| 1991 | 100 Thousand USD | 0.0% |
| 1990 | 100 Thousand USD | 0.0% |
| 1989 | 100 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -3000.00 USD | 75.0% |
| 2024 Q2 | -12 Thousand USD | 7.69% |
| 2024 Q1 | -13 Thousand USD | -109.03% |
| 2023 Q3 | -11 Thousand USD | -122.45% |
| 2023 Q2 | 49 Thousand USD | 545.45% |
| 2023 Q4 | 144 Thousand USD | 1409.09% |
| 2023 Q1 | -11 Thousand USD | -100.0% |
| 2023 FY | 49 Thousand USD | -100.0% |
| 2022 Q3 | -10 Thousand USD | 9.09% |
| 2022 Q4 | 2.46 Billion USD | 24689990.0% |
| 2022 FY | 2.46 Billion USD | 1936368.02% |
| 2022 Q1 | -10 Thousand USD | -100.31% |
| 2022 Q2 | -11 Thousand USD | -10.0% |
| 2021 Q2 | -14.63 Thousand USD | -111.48% |
| 2021 Q1 | 127.49 Thousand USD | 151.26% |
| 2021 FY | 127.49 Thousand USD | 241.42% |
| 2021 Q3 | -15.16 Thousand USD | -3.59% |
| 2021 Q4 | 3.22 Million USD | 21391.95% |
| 2020 Q3 | - USD | 0.0% |
| 2020 FY | -90.15 Thousand USD | -207.65% |
| 2020 Q1 | - USD | 100.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q4 | -248.72 Thousand USD | 0.0% |
| 2019 Q1 | - USD | 100.0% |
| 2019 Q4 | -685.21 Thousand USD | 0.0% |
| 2019 FY | 83.75 Thousand USD | -75.66% |
| 2019 Q3 | - USD | -100.0% |
| 2019 Q2 | 83.75 Thousand USD | 0.0% |
| 2018 Q2 | 249.33 Thousand USD | 1083.43% |
| 2018 FY | 344.09 Thousand USD | 33.4% |
| 2018 Q4 | -2.84 Million USD | -2442.17% |
| 2018 Q3 | 121.34 Thousand USD | -51.33% |
| 2018 Q1 | -25.35 Thousand USD | 77.14% |
| 2017 Q1 | -2121.00 USD | -101.66% |
| 2017 FY | 257.94 Thousand USD | 212.34% |
| 2017 Q4 | -110.89 Thousand USD | -150.17% |
| 2017 Q3 | 221.04 Thousand USD | 98344.0% |
| 2017 Q2 | -225.00 USD | 89.39% |
| 2016 Q1 | -59.64 Thousand USD | 99.69% |
| 2016 FY | 82.58 Thousand USD | -98.53% |
| 2016 Q4 | 128.01 Thousand USD | 330.61% |
| 2016 Q3 | 29.72 Thousand USD | 291.54% |
| 2016 Q2 | -15.52 Thousand USD | 73.98% |
| 2015 Q4 | -19.31 Million USD | -143718.52% |
| 2015 Q2 | -95.63 Thousand USD | -101.67% |
| 2015 FY | 5.6 Million USD | 233.87% |
| 2015 Q3 | 13.44 Thousand USD | 114.06% |
| 2015 Q1 | 5.71 Million USD | 4717.41% |
| 2014 Q3 | 1.02 Million USD | 80.08% |
| 2014 Q2 | 569.08 Thousand USD | 1814.22% |
| 2014 Q4 | 118.55 Thousand USD | -88.43% |
| 2014 FY | 1.67 Million USD | 2226.08% |
| 2014 Q1 | -33.19 Thousand USD | -134.18% |
| 2013 Q2 | -6750.00 USD | 72.93% |
| 2013 Q1 | -24.93 Thousand USD | -1483.3% |
| 2013 FY | 72.19 Thousand USD | -92.29% |
| 2013 Q4 | 97.12 Thousand USD | 738.8% |
| 2013 Q3 | -15.2 Thousand USD | -125.26% |
| 2012 FY | 936.13 Thousand USD | -3.4% |
| 2012 Q1 | 448.45 Thousand USD | 0.02% |
| 2012 Q4 | -1575.00 USD | -100.63% |
| 2012 Q2 | 247.57 Thousand USD | -44.79% |
| 2012 Q3 | 248.75 Thousand USD | 0.48% |
| 2011 Q2 | 62.26 Thousand USD | 429.81% |
| 2011 Q4 | 448.36 Thousand USD | 0.36% |
| 2011 Q3 | 446.73 Thousand USD | 617.5% |
| 2011 FY | 969.11 Thousand USD | 49.47% |
| 2011 Q1 | 11.75 Thousand USD | -96.13% |
| 2010 Q3 | -649.29 Thousand USD | -313.95% |
| 2010 FY | 648.36 Thousand USD | -34.52% |
| 2010 Q4 | 303.99 Thousand USD | 146.82% |
| 2010 Q2 | 303.48 Thousand USD | 1699.69% |
| 2010 Q1 | 16.86 Thousand USD | -84.95% |
| 2009 Q3 | 264.89 Thousand USD | 2.42% |
| 2009 Q1 | 354.51 Thousand USD | -62.79% |
| 2009 Q4 | 112.05 Thousand USD | -57.7% |
| 2009 FY | 990.1 Thousand USD | -49.68% |
| 2009 Q2 | 258.64 Thousand USD | -27.04% |
| 2008 FY | 1.96 Million USD | 502.63% |
| 2008 Q4 | 952.7 Thousand USD | 12.42% |
| 2008 Q3 | 847.41 Thousand USD | 561.62% |
| 2008 Q2 | 128.08 Thousand USD | 225.69% |
| 2008 Q1 | 39.32 Thousand USD | -60.31% |
| 2007 FY | 326.49 Thousand USD | -7.3% |
| 2007 Q1 | 89.55 Thousand USD | 19.42% |
| 2007 Q2 | 60.82 Thousand USD | -32.09% |
| 2007 Q3 | 77.03 Thousand USD | 26.67% |
| 2007 Q4 | 99.08 Thousand USD | 28.61% |
| 2006 FY | 352.2 Thousand USD | 225.86% |
| 2006 Q4 | 74.99 Thousand USD | -18.13% |
| 2006 Q3 | 91.6 Thousand USD | 100.51% |
| 2006 Q2 | 45.68 Thousand USD | -67.35% |
| 2006 Q1 | 139.93 Thousand USD | 220.62% |
| 2005 Q2 | -89.14 Thousand USD | -160.23% |
| 2005 FY | -279.84 Thousand USD | -187.9% |
| 2005 Q3 | -222.7 Thousand USD | -149.81% |
| 2005 Q1 | 148.01 Thousand USD | 63.34% |
| 2005 Q4 | -116 Thousand USD | 47.91% |
| 2004 Q2 | 70.1 Thousand USD | 187.3% |
| 2004 Q3 | 133.22 Thousand USD | 90.04% |
| 2004 Q4 | 90.61 Thousand USD | -31.98% |
| 2004 FY | 318.35 Thousand USD | 366.26% |
| 2004 Q1 | 24.4 Thousand USD | 222.85% |
| 2003 Q2 | 6083.00 USD | -79.25% |
| 2003 Q1 | 29.31 Thousand USD | 141.64% |
| 2003 FY | 68.27 Thousand USD | -97.94% |
| 2003 Q4 | -19.86 Thousand USD | -137.66% |
| 2003 Q3 | 52.74 Thousand USD | 767.06% |
| 2002 FY | 3.31 Million USD | 233.86% |
| 2002 Q1 | 850.91 Thousand USD | 96.04% |
| 2002 Q2 | 1.78 Million USD | 110.26% |
| 2002 Q3 | 745.98 Thousand USD | -58.31% |
| 2002 Q4 | -70.4 Thousand USD | -109.44% |
| 2001 Q3 | 304.24 Thousand USD | 51.44% |
| 2001 FY | 993.12 Thousand USD | -1.51% |
| 2001 Q4 | 434.04 Thousand USD | 42.66% |
| 2001 Q1 | 164.83 Thousand USD | -29.81% |
| 2001 Q2 | 200.89 Thousand USD | 21.88% |
| 2000 Q1 | 100 Thousand USD | 0.0% |
| 2000 Q3 | 333.5 Thousand USD | 23.39% |
| 2000 Q4 | 234.85 Thousand USD | -29.58% |
| 2000 Q2 | 270.28 Thousand USD | 170.28% |
| 2000 FY | 1 Million USD | 152.09% |
| 1999 Q4 | - USD | -100.0% |
| 1999 Q1 | 100 Thousand USD | 0.0% |
| 1999 FY | 400 Thousand USD | 0.0% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1999 Q3 | 100 Thousand USD | 0.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1998 Q1 | 200 Thousand USD | 100.0% |
| 1998 FY | 400 Thousand USD | 0.0% |
| 1998 Q4 | 100 Thousand USD | 0.0% |
| 1998 Q2 | 100 Thousand USD | -50.0% |
| 1997 Q4 | 100 Thousand USD | -50.0% |
| 1997 FY | 400 Thousand USD | 100.0% |
| 1997 Q3 | 200 Thousand USD | 100.0% |
| 1997 Q2 | 100 Thousand USD | -50.0% |
| 1997 Q1 | 200 Thousand USD | 0.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1996 Q3 | 100 Thousand USD | 0.0% |
| 1996 FY | 200 Thousand USD | 0.0% |
| 1996 Q4 | - USD | -100.0% |
| 1995 Q2 | 100 Thousand USD | 0.0% |
| 1995 Q1 | 100 Thousand USD | 0.0% |
| 1995 FY | 200 Thousand USD | 0.0% |
| 1995 Q4 | - USD | -100.0% |
| 1995 Q3 | 100 Thousand USD | 0.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q1 | 100 Thousand USD | 0.0% |
| 1994 FY | 200 Thousand USD | 100.0% |
| 1994 Q4 | - USD | -100.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| 1993 Q1 | 100 Thousand USD | 0.0% |
| 1993 FY | 100 Thousand USD | 0.0% |
| 1993 Q4 | - USD | -100.0% |
| 1992 FY | 100 Thousand USD | 0.0% |
| 1992 Q2 | 100 Thousand USD | 0.0% |
| 1992 Q3 | -400 Thousand USD | -500.0% |
| 1992 Q4 | - USD | 100.0% |
| 1992 Q1 | 100 Thousand USD | 0.0% |
| 1991 Q4 | - USD | -100.0% |
| 1991 Q2 | 100 Thousand USD | 0.0% |
| 1991 Q1 | 100 Thousand USD | 0.0% |
| 1991 Q3 | 100 Thousand USD | 0.0% |
| 1991 FY | 100 Thousand USD | 0.0% |
| 1990 Q3 | 100 Thousand USD | 0.0% |
| 1990 Q4 | - USD | -100.0% |
| 1990 Q2 | 100 Thousand USD | 0.0% |
| 1990 FY | 100 Thousand USD | 0.0% |
| 1990 Q1 | 100 Thousand USD | 0.0% |
| 1989 Q3 | 100 Thousand USD | 0.0% |
| 1989 Q1 | 100 Thousand USD | 0.0% |
| 1989 FY | 100 Thousand USD | 0.0% |
| 1989 Q2 | 100 Thousand USD | 0.0% |
| 1989 Q4 | - USD | -100.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Caribou Biosciences, Inc. | -77.59 Million USD | 100.063% |
| Inhibikase Therapeutics, Inc. | -13.35 Million USD | 100.367% |
| Alaunos Therapeutics, Inc. | -4.79 Million USD | 101.021% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 109.959% |
| Phathom Pharmaceuticals, Inc. | 515 Thousand USD | 90.485% |
| C4 Therapeutics, Inc. | -96.95 Million USD | 100.051% |
| Agenus Inc. | 139.61 Million USD | 99.965% |
| Fortress Biotech, Inc. | 57.85 Million USD | 99.915% |
| GlycoMimetics, Inc. | -143.3 Thousand USD | 134.194% |
| Novavax, Inc. | 639.93 Million USD | 99.992% |
| Keros Therapeutics, Inc. | -664 Thousand USD | 107.38% |
| Eton Pharmaceuticals, Inc. | 21.06 Million USD | 99.767% |
| CARGO Therapeutics, Inc. Common Stock | -3.69 Million USD | 101.327% |
| Entrada Therapeutics, Inc. | 29.12 Million USD | 99.832% |
| Akebia Therapeutics, Inc. | 120.47 Million USD | 99.959% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 99.997% |
| AlloVir, Inc. | -398 Thousand USD | 112.312% |
| Aptorum Group Limited | -1.11 Million USD | 104.396% |
| Ardelyx, Inc. | 106.66 Million USD | 99.954% |
| Bicycle Therapeutics plc | -129.52 Million USD | 100.038% |
| BioXcel Therapeutics, Inc. | 120 Thousand USD | 59.167% |
| Chimerix, Inc. | 324 Thousand USD | 84.877% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 100.157% |
| CRISPR Therapeutics AG | 240.95 Million USD | 99.98% |
| Clearside Biomedical, Inc. | 7.87 Million USD | 99.377% |
| Precision BioSciences, Inc. | 40.47 Million USD | 99.879% |
| Dyadic International, Inc. | 922.95 Thousand USD | 94.691% |
| Elevation Oncology, Inc. | -39 Thousand USD | 225.641% |
| Fortress Biotech, Inc. | 57.85 Million USD | 99.915% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Alkermes plc | 1.37 Billion USD | 99.996% |
| Immix Biopharma, Inc. | -5468.00 USD | 996.123% |
| Innoviva, Inc. | 261.06 Million USD | 99.981% |
| IO Biotech, Inc. | -756 Thousand USD | 106.481% |
| Jaguar Health, Inc. | 7.72 Million USD | 99.366% |
| Ligand Pharmaceuticals Incorporated | 119.75 Million USD | 99.959% |
| ContextLogic Inc. | 59 Million USD | 99.917% |
| AbCellera Biologics Inc. | 38.02 Million USD | 99.871% |
| Lantern Pharma Inc. | -174.84 Thousand USD | 128.025% |
| Kintara Therapeutics, Inc. | -55 Thousand USD | 189.091% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 99.98% |
| Madrigal Pharmaceuticals, Inc. | -527 Thousand USD | 109.298% |
| MEI Pharma, Inc. | 49.32 Million USD | 99.901% |
| Barinthus Biotherapeutics plc | 802 Thousand USD | 93.89% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Marinus Pharmaceuticals, Inc. | 29.05 Million USD | 99.831% |
| NextCure, Inc. | -3.68 Million USD | 101.33% |
| HOOKIPA Pharma Inc. | 16.57 Million USD | 99.704% |
| ChromaDex Corporation | 50.78 Million USD | 99.904% |
| IDEAYA Biosciences, Inc. | -106.12 Million USD | 100.046% |
| Incyte Corporation | 3.44 Billion USD | 99.999% |
| Opthea Limited | 21.72 Thousand USD | -125.599% |
| MiMedx Group, Inc. | 266.84 Million USD | 99.982% |
| Outlook Therapeutics, Inc. | -44.18 Thousand USD | 210.89% |
| Aadi Bioscience, Inc. | 21.54 Million USD | 99.773% |
| Psyence Biomedical Ltd. | -240.00 USD | 20516.667% |
| Vaxcyte, Inc. | -75 Million USD | 100.065% |
| PDS Biotechnology Corporation | -57.32 Thousand USD | 185.476% |
| Pharming Group N.V. | 220.1 Million USD | 99.978% |
| Pieris Pharmaceuticals, Inc. | 1 Million USD | 95.144% |
| Onconetix, Inc. | -1.12 Million USD | 104.347% |
| Acelyrin, Inc. | -115 Thousand USD | 142.609% |
| PureTech Health plc | -1.6 Million USD | 103.057% |
| Pyxis Oncology, Inc. | -2 Million USD | 102.45% |
| Avidity Biosciences, Inc. | -181.4 Million USD | 100.027% |
| TransCode Therapeutics, Inc. | -516.74 Thousand USD | 109.482% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| ESSA Pharma Inc. | -118.49 Thousand USD | 141.353% |
| Rigel Pharmaceuticals, Inc. | 109.77 Million USD | 99.955% |
| Ocuphire Pharma, Inc. | 19.04 Million USD | 99.743% |
| Seer, Inc. | 7.02 Million USD | 99.303% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 100.108% |
| SELLAS Life Sciences Group, Inc. | - USD | -Infinity% |
| Sol-Gel Technologies Ltd. | -21.98 Million USD | 100.223% |
| Salarius Pharmaceuticals, Inc. | -10.05 Thousand USD | 587.514% |
| Summit Therapeutics Inc. | -2.05 Million USD | 102.39% |
| Sensei Biotherapeutics, Inc. | -571 Thousand USD | 108.581% |
| Senti Biosciences, Inc. | -2.68 Million USD | 101.826% |
| ImmuCell Corporation | 4.39 Million USD | 98.885% |
| Syros Pharmaceuticals, Inc. | -98.21 Million USD | 100.05% |
| Janux Therapeutics, Inc. | -46.83 Million USD | 100.105% |
| Precigen, Inc. | 106 Thousand USD | 53.774% |
| Longboard Pharmaceuticals, Inc. | -5000.00 USD | 1080.0% |
| Oncternal Therapeutics, Inc. | -28.96 Million USD | 100.169% |
| Stoke Therapeutics, Inc. | 4.05 Million USD | 98.79% |
| Xeris Biopharma Holdings, Inc. | 135.26 Million USD | 99.964% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 101.243% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 99.833% |
| Verrica Pharmaceuticals Inc. | 4.37 Million USD | 98.881% |
| VistaGen Therapeutics, Inc. | 496 Thousand USD | 90.121% |
| VYNE Therapeutics Inc. | 424 Thousand USD | 88.443% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 159.756% |
| Wave Life Sciences Ltd. | 104.09 Million USD | 99.953% |
| Fate Therapeutics, Inc. | -98.16 Million USD | 100.05% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 121.121% |
| Inhibrx Biosciences, Inc. | 609 Thousand USD | 91.954% |
| Catalyst Pharmaceuticals, Inc. | 313.67 Million USD | 99.984% |
| Orchestra BioMed Holdings, Inc. | 2.57 Million USD | 98.096% |
| Alzamend Neuro, Inc. | -50.74 Thousand USD | 196.571% |
| Rocket Pharmaceuticals, Inc. | -7.09 Million USD | 100.69% |
| Aptose Biosciences Inc. | -474.54 Thousand USD | 110.326% |
| ZyVersa Therapeutics, Inc. | -10.4 Thousand USD | 571.154% |
| Soligenix, Inc. | 97.31 Thousand USD | 49.646% |
| Century Therapeutics, Inc. | -10.8 Million USD | 100.453% |
| Kura Oncology, Inc. | -849 Thousand USD | 105.771% |
| TScan Therapeutics, Inc. | -67.1 Million USD | 100.073% |
| Intensity Therapeutics, Inc. | -147 Thousand USD | 133.333% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 99.03 Million USD | 99.951% |
| Autolus Therapeutics plc | -4.86 Million USD | 101.007% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| EyePoint Pharmaceuticals, Inc. | 41.38 Million USD | 99.882% |
| Eterna Therapeutics Inc. | -168 Thousand USD | 129.167% |
| Adaptive Biotechnologies Corporation | 94.72 Million USD | 99.948% |
| GRI Bio, Inc. | 10.84 Million USD | 99.548% |
| Xenetic Biosciences, Inc. | 2.53 Million USD | 98.071% |
| Tenaya Therapeutics, Inc. | -8.68 Million USD | 100.564% |
| IGM Biosciences, Inc. | -211.66 Million USD | 100.023% |
| INmune Bio, Inc. | 155 Thousand USD | 68.387% |
| Heron Therapeutics, Inc. | 61.93 Million USD | 99.921% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 103.253% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 107.556% |
| Entero Therapeutics, Inc. | -29.27 Thousand USD | 267.384% |
| Milestone Pharmaceuticals Inc. | 402 Thousand USD | 87.811% |
| X4 Pharmaceuticals, Inc. | -1.99 Million USD | 102.455% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 115.655% |
| Coherus BioSciences, Inc. | 94.46 Million USD | 99.948% |
| Verastem, Inc. | -62 Thousand USD | 179.032% |
| Abeona Therapeutics Inc. | 2.43 Million USD | 97.988% |
| Pliant Therapeutics, Inc. | -261 Thousand USD | 118.774% |
| Tonix Pharmaceuticals Holding Corp. | 3.02 Million USD | 98.381% |
| Histogen Inc. | 3.76 Million USD | 98.7% |
| Aprea Therapeutics, Inc. | 576.17 Thousand USD | 91.496% |
| Surrozen, Inc. | -27.23 Million USD | 100.18% |
| Organovo Holdings, Inc. | -5.38 Million USD | 100.909% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Ovid Therapeutics Inc. | -1.2 Million USD | 104.067% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 100.191% |
| CASI Pharmaceuticals, Inc. | 20.05 Million USD | 99.756% |
| Cadrenal Therapeutics, Inc. Common Stock | -1980.00 USD | 2574.747% |
| Centessa Pharmaceuticals plc | 6.06 Million USD | 99.192% |
| Hepion Pharmaceuticals, Inc. | -67.13 Thousand USD | 172.992% |
| Arcturus Therapeutics Holdings Inc. | 154.79 Million USD | 99.968% |
| BioRestorative Therapies, Inc. | 145.8 Thousand USD | 66.392% |
| Apollomics, Inc. | 127 Thousand USD | 61.417% |
| Amarin Corporation plc | 165.54 Million USD | 99.97% |
| Mesoblast Limited | -9.81 Million USD | 100.499% |
| Turnstone Biologics Corp. | 16.5 Million USD | 99.703% |
| Kymera Therapeutics, Inc. | -110.48 Million USD | 100.044% |
| Synaptogenix, Inc. | -6347.00 USD | 872.018% |
| Tiziana Life Sciences Ltd | -51 Thousand USD | 196.078% |
| Aurinia Pharmaceuticals Inc. | 161.36 Million USD | 99.97% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Exelixis, Inc. | 1.75 Billion USD | 99.997% |
| Better Therapeutics, Inc. | -2.72 Million USD | 101.796% |
| Nurix Therapeutics, Inc. | -112.16 Million USD | 100.044% |
| Apellis Pharmaceuticals, Inc. | 338.08 Million USD | 99.986% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 529.523% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Gritstone bio, Inc. | -6.26 Million USD | 100.783% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 104.422% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 7.31 Million USD | 99.33% |
| Insmed Incorporated | 239.63 Million USD | 99.98% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| MediWound Ltd. | 3.57 Million USD | 98.631% |
| OmniAb, Inc. | 14.66 Million USD | 99.666% |
| Alector, Inc. | -95.05 Million USD | 100.052% |
| Seres Therapeutics, Inc. | 125.62 Million USD | 99.961% |
| Checkpoint Therapeutics, Inc. | -43.46 Million USD | 100.113% |
| Zai Lab Limited | 170.9 Million USD | 99.971% |
| Revance Therapeutics, Inc. | 81.87 Million USD | 99.94% |
| Aura Biosciences, Inc. | -1.29 Million USD | 103.784% |
| Lyell Immunopharma, Inc. | 130 Thousand USD | 62.308% |
| Immunic, Inc. | -111 Thousand USD | 144.144% |
| Tarsus Pharmaceuticals, Inc. | 15.85 Million USD | 99.691% |
| Veracyte, Inc. | 248.14 Million USD | 99.98% |
| InMed Pharmaceuticals Inc. | -6.98 Billion USD | 100.001% |
| FibroGen, Inc. | 128.9 Million USD | 99.962% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| Adial Pharmaceuticals, Inc. | -564.00 USD | 8787.943% |
| Sonnet BioTherapeutics Holdings, Inc. | -11.66 Million USD | 100.42% |
| Jazz Pharmaceuticals plc | 3.39 Billion USD | 99.999% |
| Cyclacel Pharmaceuticals, Inc. | 389 Thousand USD | 87.404% |
| Amylyx Pharmaceuticals, Inc. | 355.34 Million USD | 99.986% |
| TG Therapeutics, Inc. | 219.1 Million USD | 99.978% |
| Galecto, Inc. | -830 Thousand USD | 105.904% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 103.538% |
| Fortrea Holdings Inc. | 424 Million USD | 99.988% |
| KalVista Pharmaceuticals, Inc. | -86.16 Million USD | 100.057% |
| Aptevo Therapeutics Inc. | -567 Thousand USD | 108.642% |
| XBiotech Inc. | -1.74 Million USD | 102.81% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 104.422% |
| Lyra Therapeutics, Inc. | -46.47 Million USD | 100.105% |
| Foghorn Therapeutics Inc. | -75.53 Million USD | 100.065% |
| Y-mAbs Therapeutics, Inc. | 73.4 Million USD | 99.933% |
| Theravance Biopharma, Inc. | 16.8 Million USD | 99.708% |
| Ultragenyx Pharmaceutical Inc. | 389.04 Million USD | 99.987% |
| Metagenomi, Inc. Common Stock | -49.64 Million USD | 100.099% |
| Vaxxinity, Inc. | -2.23 Million USD | 102.193% |
| BioCryst Pharmaceuticals, Inc. | 326.75 Million USD | 99.985% |
| Gain Therapeutics, Inc. | -11.32 Million USD | 100.433% |
| Cartesian Therapeutics, Inc. | 24.45 Million USD | 99.8% |
| NexImmune, Inc. | -1.02 Million USD | 104.781% |
| Creative Medical Technology Holdings, Inc. | 5400.00 USD | -807.407% |
| Marker Therapeutics, Inc. | -7.1 Million USD | 100.69% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.0% |
| Chemomab Therapeutics Ltd. | -66.82 Thousand USD | 173.324% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | -3.55 Million USD | 101.38% |
| Ainos, Inc. | -253.73 Thousand USD | 119.312% |
| Pluri Inc. | 322 Thousand USD | 84.783% |
| Prothena Corporation plc | -129.2 Million USD | 100.038% |
| Adaptimmune Therapeutics plc | 50.42 Million USD | 99.903% |
| Celularity Inc. | 6.75 Million USD | 99.275% |
| Rallybio Corporation | -150 Thousand USD | 132.667% |
| Cue Biopharma, Inc. | -32.6 Million USD | 100.15% |
| MeiraGTx Holdings plc | 287 Thousand USD | 82.927% |
| Omeros Corporation | -69.77 Million USD | 100.07% |
| Humacyte, Inc. | -76.55 Million USD | 100.064% |
| Immunocore Holdings plc | 248.39 Million USD | 99.98% |
| Cocrystal Pharma, Inc. | -15.16 Million USD | 100.323% |
| Cidara Therapeutics, Inc. | 62.38 Million USD | 99.921% |
| Blueprint Medicines Corporation | 236.58 Million USD | 99.979% |
| CalciMedica, Inc. | -58 Thousand USD | 184.483% |
| Cabaletta Bio, Inc. | -1.42 Million USD | 103.436% |
| Scholar Rock Holding Corporation | -2.84 Million USD | 101.723% |
| Sana Biotechnology, Inc. | -30.86 Million USD | 100.159% |
| Pulmatrix, Inc. | -8.22 Million USD | 100.596% |
| Elicio Therapeutics, Inc. | -1.17 Million USD | 104.188% |
| Vigil Neuroscience, Inc. | -399 Thousand USD | 112.281% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 100.012% |
| Adlai Nortye Ltd. American Depositary Shares | 2.77 Million USD | 98.235% |
| Cytokinetics, Incorporated | -322.59 Million USD | 100.015% |
| Eloxx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 862.1 Thousand USD | 94.316% |
| Protara Therapeutics, Inc. | -341 Thousand USD | 114.37% |
| Vor Biopharma Inc. | -3.49 Million USD | 101.403% |
| Roivant Sciences Ltd. | 109.23 Million USD | 99.955% |
| Evogene Ltd. | 1.39 Million USD | 96.497% |
| ProKidney Corp. | -3.16 Million USD | 101.546% |
| Applied Therapeutics, Inc. | -43.91 Million USD | 100.112% |
| Hoth Therapeutics, Inc. | - USD | -Infinity% |
| BridgeBio Pharma, Inc. | 6.85 Million USD | 99.285% |
| CorMedix Inc. | -205.56 Thousand USD | 123.837% |
| BioLineRx Ltd. | 1.1 Million USD | 95.578% |
| Tango Therapeutics, Inc. | -78.67 Million USD | 100.062% |
| Galectin Therapeutics Inc. | -33 Thousand USD | 248.485% |
| Atai Life Sciences N.V. | -5000.00 USD | 1080.0% |
| Renovaro Biosciences Inc. | -121.85 Thousand USD | 140.21% |
| Aerovate Therapeutics, Inc. | -96 Thousand USD | 151.042% |
| Zentalis Pharmaceuticals, Inc. | -1.38 Million USD | 103.528% |
| Sagimet Biosciences Inc. | 2 Million USD | 97.55% |
| MediciNova, Inc. | 979.7 Thousand USD | 94.998% |
| Praxis Precision Medicines, Inc. | -84.31 Million USD | 100.058% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 151.822% |
| GeoVax Labs, Inc. | -20.72 Million USD | 100.236% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 99.98% |
| Biomea Fusion, Inc. | -4.2 Million USD | 101.166% |
| PTC Therapeutics, Inc. | 872.33 Million USD | 99.994% |
| Mereo BioPharma Group plc | 7.42 Million USD | 99.34% |
| Cullinan Oncology, Inc. | -310 Thousand USD | 115.806% |
| Syndax Pharmaceuticals, Inc. | -12 Thousand USD | 508.333% |
| Absci Corporation | -41.84 Million USD | 100.117% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 1080.0% |
| 4D Molecular Therapeutics, Inc. | -76.37 Million USD | 100.064% |
| Dyne Therapeutics, Inc. | -2.46 Million USD | 101.991% |
| Kiniksa Pharmaceuticals, Ltd. | 213.73 Million USD | 99.977% |
| Ventyx Biosciences, Inc. | -941 Thousand USD | 105.207% |
| Allakos Inc. | -6.14 Million USD | 100.798% |
| Imunon, Inc. | -720 Thousand USD | 106.806% |
| Fulcrum Therapeutics, Inc. | -68.99 Million USD | 100.071% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 99.99% |
| BioAtla, Inc. | -103.73 Million USD | 100.047% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 529.523% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | 127.528% |
| Allogene Therapeutics, Inc. | -242.81 Million USD | 100.02% |
| Larimar Therapeutics, Inc. | -311 Thousand USD | 115.756% |
| XOMA Corporation | 3.86 Million USD | 98.731% |
| Kezar Life Sciences, Inc. | -70.08 Million USD | 100.07% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 99.669% |
| aTyr Pharma, Inc. | -2.38 Million USD | 102.052% |
| Aligos Therapeutics, Inc. | 12.46 Million USD | 99.607% |
| Akero Therapeutics, Inc. | -29 Thousand USD | 268.966% |
| Viridian Therapeutics, Inc. | -1 Million USD | 104.861% |
| Eliem Therapeutics, Inc. | - USD | -Infinity% |
| EyeGate Pharmaceuticals, Inc. | 13.00 USD | -376823.077% |
| Akari Therapeutics, Plc | -4000.00 USD | 1325.0% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 99.992% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | 74.834% |
| UroGen Pharma Ltd. | 73.35 Million USD | 99.933% |
| Sutro Biopharma, Inc. | -26.69 Million USD | 100.184% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | -322.05% |
| Orgenesis Inc. | -5.72 Million USD | 100.856% |
| Entera Bio Ltd. | -56 Thousand USD | 187.5% |
| GH Research PLC | -315 Thousand USD | 115.556% |
| Lisata Therapeutics, Inc. | -189 Thousand USD | 125.926% |
| Reneo Pharmaceuticals, Inc. | -525 Thousand USD | 109.333% |
| Xencor, Inc. | -85.26 Million USD | 100.057% |
| 60 Degrees Pharmaceuticals, Inc. | -220.97 Thousand USD | 122.174% |
| Replimune Group, Inc. | -2.65 Million USD | 101.846% |
| Coeptis Therapeutics Holdings, Inc. | -1 Million USD | 104.894% |
| Vanda Pharmaceuticals Inc. | 177.84 Million USD | 99.972% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | 74.834% |
| Portage Biotech Inc. | -54 Thousand USD | 190.741% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 151.822% |
| Olema Pharmaceuticals, Inc. | -377 Thousand USD | 112.997% |
| OncoCyte Corporation | 413 Thousand USD | 88.136% |
| Qualigen Therapeutics, Inc. | -4495.00 USD | 1190.1% |
| Processa Pharmaceuticals, Inc. | -222.00 USD | 22172.072% |
| Purple Biotech Ltd. | -196 Thousand USD | 125.0% |
| CollPlant Biotechnologies Ltd. | 8.96 Million USD | 99.454% |
| scPharmaceuticals Inc. | 9.78 Million USD | 99.499% |
| ProMIS Neurosciences, Inc. | -10.44 Million USD | 100.469% |
| HilleVax, Inc. | -2.15 Million USD | 102.273% |
| NeuroSense Therapeutics Ltd. | -97 Thousand USD | 150.515% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | -15 Thousand USD | 426.58% |
| Neumora Therapeutics, Inc. Common Stock | -668 Thousand USD | 107.335% |
| Atossa Therapeutics, Inc. | -23 Thousand USD | 313.043% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | -7506.16 USD | 752.797% |
| Savara Inc. | -44.26 Million USD | 100.111% |
| Curis, Inc. | 9.81 Million USD | 99.501% |
| Daré Bioscience, Inc. | 2.76 Million USD | 98.231% |
| Carmell Therapeutics Corporation | -124.78 Thousand USD | 139.267% |
| Titan Pharmaceuticals, Inc. | -1.72 Million USD | 102.834% |
| Achieve Life Sciences, Inc. | -228 Thousand USD | 121.491% |
| BeiGene, Ltd. | 2.07 Billion USD | 99.998% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 101.753% |
| Revolution Medicines, Inc. Warrant | -399.66 Million USD | 100.012% |
| Protagonist Therapeutics, Inc. | 56.68 Million USD | 99.914% |
| Erasca, Inc. | -3.73 Million USD | 101.313% |
| bluebird bio, Inc. | -4.03 Million USD | 101.216% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 273.648% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 99.997% |
| DBV Technologies S.A. | 15.72 Million USD | 99.688% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 273.648% |
| Moderna, Inc. | 2.15 Billion USD | 99.998% |
| Vincerx Pharma, Inc. | -915 Thousand USD | 105.355% |
| Fresh Tracks Therapeutics, Inc. | 8 Million USD | 99.388% |
| Molecular Templates, Inc. | 50.39 Million USD | 99.903% |
| Acrivon Therapeutics, Inc. Common Stock | -536 Thousand USD | 109.142% |
| Travere Therapeutics, Inc. | 133.78 Million USD | 99.963% |
| Monte Rosa Therapeutics, Inc. | -6.22 Million USD | 100.788% |
| Spruce Biosciences, Inc. | -39.34 Million USD | 100.125% |
| Celldex Therapeutics, Inc. | -111.12 Million USD | 100.044% |
| Cogent Biosciences, Inc. | -3.58 Million USD | 101.366% |
| MacroGenics, Inc. | 50.52 Million USD | 99.903% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | -6.09 Million USD | 100.804% |
| Prime Medicine, Inc. | -147.9 Million USD | 100.033% |
| Aditxt, Inc. | -111.66 Thousand USD | 143.883% |
| Adagene Inc. | 18.11 Million USD | 99.729% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 488 Thousand USD | 89.959% |
| Maravai LifeSciences Holdings, Inc. | 140.2 Million USD | 99.965% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 157.83 Million USD | 99.969% |
| SciSparc Ltd. | 2.19 Million USD | 97.769% |
| Vericel Corporation | 135.57 Million USD | 99.964% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 295.617% |
| Minerva Neurosciences, Inc. | -30.98 Thousand USD | 258.156% |
| Generation Bio Co. | -73.91 Million USD | 100.066% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | -437 Thousand USD | 111.213% |
| Arcutis Biotherapeutics, Inc. | 54.61 Million USD | 99.91% |
| Invivyd, Inc. | -2.02 Million USD | 102.416% |
| Relay Therapeutics, Inc. | -300.84 Million USD | 100.016% |
| Quoin Pharmaceuticals, Ltd. | -103.43 Thousand USD | 147.371% |
| Spero Therapeutics, Inc. | 96.36 Million USD | 99.949% |
| Artelo Biosciences, Inc. | - USD | -Infinity% |
| 2seventy bio, Inc. | 98.28 Million USD | 99.95% |
| ADMA Biologics, Inc. | 88.21 Million USD | 99.944% |
| Clene Inc. | 533 Thousand USD | 90.807% |
| Capricor Therapeutics, Inc. | 24.1 Million USD | 99.797% |
| Boundless Bio, Inc. Common Stock | -957 Thousand USD | 105.12% |
| GeoVax Labs, Inc. | -20.72 Million USD | 100.236% |
| Recursion Pharmaceuticals, Inc. | 1.98 Million USD | 97.535% |
| Citius Pharmaceuticals, Inc. | -194.31 Thousand USD | 125.217% |
| Contineum Therapeutics, Inc. Class A Common Stock | 49.8 Million USD | 99.902% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 100.691% |
| ALX Oncology Holdings Inc. | -836 Thousand USD | 105.861% |
| Vir Biotechnology, Inc. | 83.41 Million USD | 99.941% |
| Evaxion Biotech A/S | 73.11 Thousand USD | 32.98% |
| Ocular Therapeutix, Inc. | 53.16 Million USD | 99.908% |
| Verve Therapeutics, Inc. | -173.18 Million USD | 100.028% |
| Trevena, Inc. | 1.45 Million USD | 96.632% |
| Surrozen, Inc. | -27.23 Million USD | 100.18% |
| Tyra Biosciences, Inc. | -353 Thousand USD | 113.881% |
| Cingulate Inc. | -582.91 Thousand USD | 108.406% |
| Galmed Pharmaceuticals Ltd. | -31 Thousand USD | 258.065% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 100.249% |
| Tenax Therapeutics, Inc. | -7570.00 USD | 747.292% |
| Terns Pharmaceuticals, Inc. | -881 Thousand USD | 105.562% |
| ACADIA Pharmaceuticals Inc. | 680.7 Million USD | 99.993% |
| Connect Biopharma Holdings Limited | -988 Thousand USD | 104.96% |
| Clearmind Medicine Inc. | -56.34 Thousand USD | 186.969% |
| Kronos Bio, Inc. | 1.37 Million USD | 96.429% |
| Bolt Biotherapeutics, Inc. | -53.66 Million USD | 100.091% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 116.781% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 110.035% |
| ImmunityBio, Inc. | -17.89 Million USD | 100.274% |
| Korro Bio, Inc. | -3.63 Million USD | 101.35% |
| Kineta, Inc. | 5.43 Million USD | 99.098% |
| BioVie Inc. | -229.37 Thousand USD | 121.362% |
| Codexis, Inc. | 57.33 Million USD | 99.915% |
| Celularity Inc. | 6.75 Million USD | 99.275% |
| Crinetics Pharmaceuticals, Inc. | 4.01 Million USD | 98.779% |
| Celcuity Inc. | -142.77 Thousand USD | 134.32% |
| Virax Biolabs Group Limited | 50.59 Thousand USD | 3.143% |
| Cibus, Inc. | 1.42 Million USD | 96.554% |
| Eledon Pharmaceuticals, Inc. | -374 Thousand USD | 113.102% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 100.214% |
| IN8bio, Inc. | -2.5 Million USD | 101.959% |
| Kodiak Sciences Inc. | -25.94 Million USD | 100.189% |
| Annexon, Inc. | -3.26 Million USD | 101.5% |
| Adverum Biotechnologies, Inc. | -2.04 Million USD | 102.397% |
| Assembly Biosciences, Inc. | -41.73 Million USD | 100.117% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | 92.344% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 99.994% |
| Eyenovia, Inc. | - USD | -Infinity% |
| Puma Biotechnology, Inc. | 172.95 Million USD | 99.972% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Xilio Therapeutics, Inc. | -1.9 Million USD | 102.579% |
| Arcellx, Inc. | 108.27 Million USD | 99.955% |
| Cardiff Oncology, Inc. | -32.36 Million USD | 100.151% |
| Enanta Pharmaceuticals, Inc. | 79.2 Million USD | 99.938% |
| Regulus Therapeutics Inc. | -21.15 Million USD | 100.232% |
| Moolec Science SA | -143.3 Thousand USD | 134.193% |
| Acumen Pharmaceuticals, Inc. | -42.31 Million USD | 100.116% |
| Geron Corporation | -123.5 Million USD | 100.04% |
| LAVA Therapeutics N.V. | 3.28 Million USD | 98.509% |
| Royalty Pharma plc | 1.79 Billion USD | 99.997% |
| Atea Pharmaceuticals, Inc. | -70.09 Million USD | 100.07% |
| Greenwich LifeSciences, Inc. | -3612.00 USD | 1456.589% |
| TFF Pharmaceuticals, Inc. | 231.39 Thousand USD | 78.824% |
| Mersana Therapeutics, Inc. | -111.41 Million USD | 100.044% |
| Humacyte, Inc. | -76.55 Million USD | 100.064% |
| Structure Therapeutics Inc. | -949.17 Thousand USD | 105.162% |
| 89bio, Inc. | -273 Thousand USD | 117.949% |
| PMV Pharmaceuticals, Inc. | -1.25 Million USD | 103.898% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | -848 Thousand USD | 105.778% |
| Trevi Therapeutics, Inc. | -123 Thousand USD | 139.837% |
| Lexicon Pharmaceuticals, Inc. | 1.11 Million USD | 95.621% |
| Notable Labs, Ltd. | 113 Thousand USD | 56.637% |
| Liquidia Corporation | 14.6 Million USD | 99.664% |
| Mustang Bio, Inc. | -2.22 Million USD | 102.202% |
| Immunovant, Inc. | -231 Thousand USD | 121.212% |
| Quantum-Si incorporated | 488 Thousand USD | 89.959% |
| Arbutus Biopharma Corporation | -55.55 Million USD | 100.088% |
| DiaMedica Therapeutics Inc. | -30 Thousand USD | 263.333% |
| Vera Therapeutics, Inc. | 1.86 Million USD | 97.368% |
| Acasti Pharma Inc. | -11 Thousand USD | 545.455% |
| MiNK Therapeutics, Inc. | -204.61 Thousand USD | 123.947% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 107.556% |
| Xenon Pharmaceuticals Inc. | -167.51 Million USD | 100.029% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | 95.681% |
| NeuroBo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Tempest Therapeutics, Inc. | -381 Thousand USD | 112.861% |
| Soleno Therapeutics, Inc. | -1.95 Million USD | 102.503% |
| PepGen Inc. | -1.18 Million USD | 104.139% |
| Moleculin Biotech, Inc. | -127 Thousand USD | 138.583% |
| United Therapeutics Corporation | 2.07 Billion USD | 99.998% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 100.214% |
| Solid Biosciences Inc. | -76.56 Million USD | 100.064% |
| BriaCell Therapeutics Corp. | -82.58 Thousand USD | 159.334% |
| Immuneering Corporation | -764.13 Thousand USD | 106.412% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | 66.26 Thousand USD | 26.053% |
| Belite Bio, Inc | -399 Thousand USD | 112.281% |
| XOMA Corporation | 3.86 Million USD | 98.731% |
| ARS Pharmaceuticals, Inc. | -20.03 Million USD | 100.245% |
| Bionomics Limited | -434.44 Thousand USD | 111.279% |
| Apogee Therapeutics, Inc. | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 104.562% |
| uniQure N.V. | 2.21 Million USD | 97.788% |
| Cassava Sciences, Inc. | -89.42 Million USD | 100.055% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | -92.06 Million USD | 100.053% |
| Forte Biosciences, Inc. | -9000.00 USD | 644.444% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | -835 Thousand USD | 105.868% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| FibroBiologics, Inc. Common Stock | -437 Thousand USD | 111.213% |
| Altimmune, Inc. | -65.37 Million USD | 100.075% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 99.986% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 104.562% |
| Compugen Ltd. | 31.45 Million USD | 99.844% |
| Peak Bio, Inc. | 367.76 Thousand USD | 86.676% |
| Zevra Therapeutics, Inc. | 24.51 Million USD | 99.8% |
| Benitec Biopharma Inc. | 108 Thousand USD | 54.63% |
| Spyre Therapeutics, Inc. | -78 Thousand USD | 162.821% |
| NKGen Biotech, Inc. Common Stock | -1.2 Million USD | 104.073% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | -1.82 Million USD | 102.689% |
| Aileron Therapeutics, Inc. | -119 Thousand USD | 141.176% |
| NKGen Biotech, Inc. Warrants | -1.2 Million USD | 104.073% |
| Instil Bio, Inc. | -4.75 Million USD | 101.03% |
| argenx SE | 1.1 Billion USD | 99.996% |
| Immunome, Inc. | -8.9 Million USD | 100.55% |
| Compass Therapeutics, Inc. | -1.89 Million USD | 102.593% |
| Verona Pharma plc | -679.62 Thousand USD | 107.21% |
| enGene Holdings Inc. Warrants | -175 Thousand USD | 128.0% |
| Shattuck Labs, Inc. | -2.38 Million USD | 102.055% |
| CervoMed Inc. | -1.29 Million USD | 103.788% |
| LENZ Therapeutics, Inc. | -2.4 Million USD | 102.036% |
| Plus Therapeutics, Inc. | -4.77 Million USD | 101.026% |
| Dianthus Therapeutics, Inc. | 2.47 Million USD | 98.017% |
| Moolec Science SA | -143.3 Thousand USD | 134.193% |
| Enveric Biosciences, Inc. | -408.03 Thousand USD | 112.009% |
| Inovio Pharmaceuticals, Inc. | -2.67 Million USD | 101.834% |
| AnaptysBio, Inc. | 14.78 Million USD | 99.668% |
| Design Therapeutics, Inc. | -537 Thousand USD | 109.125% |
| Leap Therapeutics, Inc. | -427 Thousand USD | 111.475% |
| NeurAxis, Inc. | 2.15 Million USD | 97.728% |
| Seelos Therapeutics, Inc. | 2.14 Million USD | 97.717% |
| Lumos Pharma, Inc. | 2 Million USD | 97.559% |
| Achilles Therapeutics plc | -4.73 Million USD | 101.036% |
| enGene Holdings Inc. Common Stock | -175 Thousand USD | 128.0% |
| 180 Life Sciences Corp. | -105.67 Thousand USD | 146.369% |
| Opiant Pharmaceuticals, Inc. | 31.65 Million USD | 99.845% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 862.1 Thousand USD | 94.316% |
| ORIC Pharmaceuticals, Inc. | -1.03 Million USD | 104.748% |
| CG Oncology, Inc. Common stock | -45.54 Million USD | 100.108% |
| Fractyl Health, Inc. Common Stock | 43 Thousand USD | -13.953% |
| Rani Therapeutics Holdings, Inc. | -822 Thousand USD | 105.961% |
| MoonLake Immunotherapeutics | -13.15 Thousand USD | 472.397% |
| Palisade Bio, Inc. | 246 Thousand USD | 80.081% |
| Tourmaline Bio, Inc. | -33 Thousand USD | 248.485% |
| Beam Therapeutics Inc. | -59.67 Million USD | 100.082% |
| Neurogene Inc. | -3.26 Million USD | 101.502% |
| Mirum Pharmaceuticals, Inc. | 139.33 Million USD | 99.965% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| Sesen Bio, Inc. | 40 Million USD | 99.878% |
| Enliven Therapeutics, Inc. | -297 Thousand USD | 116.498% |
| Kiora Pharmaceuticals, Inc. | -4.02 Million USD | 101.217% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 100.512% |
| Taysha Gene Therapies, Inc. | 14.08 Million USD | 99.652% |
| Athira Pharma, Inc. | -969 Thousand USD | 105.057% |
| Vaccinex, Inc. | -16 Million USD | 100.306% |
| HCW Biologics Inc. | -574.82 Thousand USD | 108.524% |
| XOMA Corporation | 3.86 Million USD | 98.731% |
| Nektar Therapeutics | 53.47 Million USD | 99.908% |
| Arvinas, Inc. | 71.8 Million USD | 99.932% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Merus N.V. | -83.46 Million USD | 100.059% |
| Omega Therapeutics, Inc. | -62.77 Million USD | 100.078% |
| Quince Therapeutics, Inc. | -322 Thousand USD | 115.217% |
| Rezolute, Inc. | -36 Thousand USD | 236.111% |
| Clene Inc. | 533 Thousand USD | 90.807% |
| Indaptus Therapeutics, Inc. | -1284.00 USD | 3916.199% |
| BeyondSpring Inc. | 1.75 Million USD | 97.202% |
| Synlogic, Inc. | -1.92 Million USD | 102.547% |
| Allarity Therapeutics, Inc. | -37 Thousand USD | 232.432% |
| Phio Pharmaceuticals Corp. | -6.33 Million USD | 100.774% |
| Peak Bio, Inc. | 367.76 Thousand USD | 86.676% |
| Werewolf Therapeutics, Inc. | -18.96 Million USD | 100.258% |
| Krystal Biotech, Inc. | 47.6 Million USD | 99.897% |
| Karyopharm Therapeutics Inc. | 141.09 Million USD | 99.965% |
| SpringWorks Therapeutics, Inc. | 5.02 Million USD | 99.025% |
| Lipella Pharmaceuticals Inc. | -2.58 Million USD | 101.892% |
| MannKind Corporation | 136.19 Million USD | 99.964% |
| Ikena Oncology, Inc. | -50.49 Million USD | 100.097% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 108.81 Million USD | 99.955% |
| Gossamer Bio, Inc. | -4.38 Million USD | 101.117% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | -252 Thousand USD | 119.444% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 1080.0% |
| Legend Biotech Corporation | 140.92 Million USD | 99.965% |
| Mural Oncology plc | -2.56 Million USD | 101.909% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 108.893% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Disc Medicine, Inc. | -100 Thousand USD | 149.0% |
| Champions Oncology, Inc. | 20.75 Million USD | 99.764% |
| REGENXBIO Inc. | 53.02 Million USD | 99.908% |
| Ensysce Biosciences, Inc. | -5.35 Million USD | 100.915% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | -192.37 Thousand USD | 125.471% |
| Edgewise Therapeutics, Inc. | -1.73 Million USD | 102.829% |
| Vaxart, Inc. | -60.76 Million USD | 100.081% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -262.78 Thousand USD | 118.647% |
| Cellectis S.A. | 18 Thousand USD | -172.222% |
| Longeveron Inc. | 221 Thousand USD | 77.828% |
| Repare Therapeutics Inc. | -80.07 Million USD | 100.061% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 99.996% |
| Inozyme Pharma, Inc. | -1.29 Million USD | 103.787% |
| Revolution Medicines, Inc. | -399.66 Million USD | 100.012% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | -35 Thousand USD | 240.0% |
| ArriVent BioPharma, Inc. Common Stock | - USD | -Infinity% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.999% |
| Denali Therapeutics Inc. | -93.34 Million USD | 100.052% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 295.617% |
| Veru Inc. | 7.56 Million USD | 99.352% |
| Corvus Pharmaceuticals, Inc. | -151 Thousand USD | 132.45% |
| Cingulate Inc. | -582.91 Thousand USD | 108.406% |
| Passage Bio, Inc. | -3.72 Million USD | 101.317% |
| Context Therapeutics Inc. | -12.04 Thousand USD | 506.842% |
| Exicure, Inc. | -1.42 Million USD | 103.443% |
| Day One Biopharmaceuticals, Inc. | -383 Thousand USD | 112.794% |
| Oramed Pharmaceuticals Inc. | 2.7 Million USD | 98.187% |
| Scinai Immunotherapeutics Ltd. | -512.67 Thousand USD | 109.558% |
| Rhythm Pharmaceuticals, Inc. | 68.12 Million USD | 99.928% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | -149.6 Thousand USD | 132.752% |
| Carisma Therapeutics, Inc. | -59.2 Million USD | 100.083% |
| Unicycive Therapeutics, Inc. | 391 Thousand USD | 87.468% |
| OmniAb, Inc. | 14.66 Million USD | 99.666% |
| Anew Medical, Inc. | - USD | -Infinity% |
| Fennec Pharmaceuticals Inc. | 19.99 Million USD | 99.755% |
| Lipocine Inc. | -2.85 Million USD | 101.719% |
| Lexeo Therapeutics, Inc. Common Stock | -1.84 Million USD | 102.659% |
| Nautilus Biotechnology, Inc. | -5.7 Million USD | 100.859% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 103.253% |
| G1 Therapeutics, Inc. | 75.31 Million USD | 99.935% |
| Bellerophon Therapeutics, Inc. | -65 Thousand USD | 175.385% |
| Sage Therapeutics, Inc. | 84.29 Million USD | 99.942% |
| Ocugen, Inc. | -33.53 Million USD | 100.146% |
| Mind Medicine (MindMed) Inc. | -3.16 Million USD | 101.55% |
| Q32 Bio Inc. | 578 Thousand USD | 91.522% |
| Brainstorm Cell Therapeutics Inc. | -265 Thousand USD | 118.491% |
| Alumis Inc. Common Stock | -1.28 Million USD | 103.816% |
| Equillium, Inc. | 35.95 Million USD | 99.864% |
| Kyverna Therapeutics, Inc. | -1.7 Million USD | 102.871% |
| Coya Therapeutics, Inc. | 500.67 Thousand USD | 90.213% |
| CNS Pharmaceuticals, Inc. | -4134.00 USD | 1285.293% |
| Galera Therapeutics, Inc. | -259 Thousand USD | 118.919% |
| Evelo Biosciences, Inc. | - USD | -Infinity% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 88.408% |
| Dominari Holdings Inc. | 2.03 Million USD | 97.597% |
| Edesa Biotech, Inc. | -183.47 Thousand USD | 126.707% |
| vTv Therapeutics Inc. | -13.59 Million USD | 100.36% |
| Bio-Techne Corporation | 773.07 Million USD | 99.994% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 99.717% |
| Harmony Biosciences Holdings, Inc. | 460.78 Million USD | 99.989% |
| Prelude Therapeutics Incorporated | -1.16 Million USD | 104.192% |
| Candel Therapeutics, Inc. | -23.98 Million USD | 100.204% |
| iTeos Therapeutics, Inc. | 11.69 Million USD | 99.581% |
| Nkarta, Inc. | -5.86 Million USD | 100.835% |
| BioCardia, Inc. | -7.24 Million USD | 100.676% |
| Iterum Therapeutics plc | -1.75 Million USD | 102.8% |